AGL
agilon health, inc. (AGL) Risks & Opportunities Analysis (2026)
Overall Score
Profitability
Margins remain negative, with TTM net profit margin at -4.24% and EBIT margin at -4.43%.
Return metrics are deeply negative, including ROE at -119.35% and ROIC at -90.22%.
Cash Flow
Operating cash flow is negative, with TTM operating cash flow per share at -4.33 and free cash flow per share at -5.93.
Free cash flow yield remains negative at -6.71%, indicating ongoing cash burn.
Balance Sheet
Liquidity is acceptable with a current ratio of 1.08 and quick ratio of 1.08.
Leverage appears manageable, with debt-to-equity at 0.15 and net debt to EBITDA at 0.32.
Valuation
The stock screens cheap on sales at 0.25x EV/sales and 0.25x price/sales.
However, negative earnings and cash flow keep earnings-based valuation metrics distorted and limit confidence in the discount.
Operational Efficiency
Asset turnover is strong at 3.72x, but profitability conversion remains poor.
The cash conversion cycle is 48.39 days, reflecting working-capital drag despite solid receivables turnover.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on agilon health, inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

